Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Review about the subsidiary Maxxon Energy, sounds like a well managed company. ;)
https://www.facebook.com/Maxxon-Energy-282076501892125/
Justin Jeffers
When I started at Maxxon it was just barely starting out in Hobbs. Manager was cool, worked with him at a prior place of employment. Then we went without work for awhile or had barely any loads at all. Only took home a 1000 every 2 weeks. Then the idiot CEO got involved running the yard because they got a big contract(plains). Work picked up which was fine but I was behind on a lot of the bills and asked for a cash advance of $600, and the only reason he said he gave it to me was because I served in the military and not to tell anyone about it. I thought that was stupid because the real reason I needed it was because they didn't give enough work prior to this. They also say to cheat your logs if you want to make money or so they can keep the contracts so some drivers work over 20 hours straight sometimes. The don't provide uniforms. They don't have good equipment. The trailer pressure tests aren't up to date on half of their trailers last time I checked. They lied to the big contractor about how much oil was hauled on at least one occasion. I noticed they put $80000 starting pay on the last indeed post, that's a lie. And finally I was fired in August for putting in an application with another company and the CEO said he didn't like giving out proprietary information to other employers like my urinalysis results so I can get hired at a better paying company and he said I had been late everyday since June 15 yet I was on military duty at the time. CEO is an anti military, you do everything I say or your fired, low paying, cheat your logs or your fired and you still owe me everything kinda guy...but I still got the job I was applying for so thanks for the time off you discriminatory piece of garbage.
Why is the stock up from .0006 to .0055? Company has since two years notes at .03 and diluted triple zero.
Cataldo took over OXIS when it had 591m o/s 2014 and decided for the split which happened December 2015.
He did it without dilution 18 months later.
Compeletely different situation now.
If you take over and want to build a new company you don´t want to start with 591m O/s. Happens also in every merger stock.
There is no 8-k about what you post. Please post a link.
The S-1 is not effective. It´s only a prospectus which was already filed first time in August 2016. S-1 is meaningless as long it´s not effective. People explained this already to you.
Your post sounds like there is an 8-k with an increase of the authorized shares and this is not true!
You warn about 300m a/s and you don´t understand that the stock is now at .018. This would be still a good share structure.
Tell us how many shares company issued since ceo took over 2014? I see only these 115m shares. And the a/s was for a long time from 2014-December 2015 maxed.
150m authorized shares.
Yes still small and probably they sold most it last days.
8-k is out:
ITEM 3.02 Unregistered Sales of Equity Securities.
The Registrant has issued a total of 42,263,842 shares of common stock (the "Shares") to a total of four entities or individuals in exchange for the cancellation of debt in the total amount of $482,455 and interest in the total amount of $79,924. The issuance was exempt from the registration requirements of Section 5 of the Securities Act of 1933 pursuant to Section 4(2) of the same Act since the issuance of the Shares did not involve any public offering. Following the issuances, the Registrant has a total of 115,215,073 shares of common stock issued and outstanding.
Sorry, if you don´t see the difference between companies which release only news and some with FDA clinical trials since years, and which went through phase 1, i cannot help you.
They went through phase 1, this was completed. Now they are in phase 1/2 and Primary Completion Date is June 2017.
This is not only talk. Do you know the costs of a FDA clinical trial?
https://clinicaltrials.gov/ct2/show?term=DT2219ARL&rank=2
"Estimated Enrollment: 44
Study Start Date: December 2015
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)"
"This study has been completed."
https://clinicaltrials.gov/ct2/show?term=DT2219ARL&rank=1
What i see, phase 1/2 FDA clinical trial, cancer drugs, cannabinoid drug, license agreement with Minnesota university, more trials planned, in the process of acquiring 4 high potential drugs, catalyst FDA results in June, patents, QB, 150m authorized shares and market cap below $2m.
There are much worse stocks, in fact there is not one which offers something similar and trades at this level and i doubt you find one with a cancer drug in phase 1/2 and results in June 2017!
No t-trade yesterday, no t-trade today, the trading could look better, but people accumulated at bid. VNDM is gone since yesterday, ARXS left also, there is only ARCA left.
Todays pr was good, but what we need are more buys, more volume or slower dilution. Thats the only issue here.
And btw there was no run. A person who posts there was a run, doesn´t know what a run is.
I see in your post history you bought this "POS" at $2 LAST YEAR and you have seen huge potential and now you tell the people who buy at .02 and below we are idiots and have too much phantasy?
Can you tell me what has changed since it was $2 beside limited dilution?
I understand your frustration, but now it´s extremely undervalued.
Oxis International Enters into a Sponsored Research Agreement with the University of Minnesota
LOS ANGELES, CA / ACCESSWIRE / March 23, 2017 / Oxis International Inc. (OTCQB: OXIS and Euronext Paris OXI.PA) announced today that it has entered into a sponsored research agreement with the University of Minnesota to conduct a toxicity study of its TriKE cancer treatment (OXS-3550), a required step before researchers can apply for a Phase 1 clinical trial with the Food and Drug Administration.
Under the agreement, Oxis will pay for the university to conduct a study that will determine the optimal dose for OXS-3550. The research will be led by Dr. Daniel Vallera, Director of the section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center. He is a member of the Scientific Advisory Board of Oxis' wholly owned subsidiary, Oxis Biotech Inc.
Oxis and the University of Minnesota have reached a licensing agreement under which Oxis holds the worldwide rights to commercialize the TriKE therapy, once it receives regulatory approval.
"The agreement will support the TriKE toxicology studies that are needed for an FDA submission, which we expect to file soon," said Dr. Jeffrey Miller, Deputy Director of the University of Minnesota Masonic Cancer Center. "We are excited to see this drug development move forward."
Dr. Vallera and Dr. Miller were instrumental in developing Trispecific Killer Engager (TriKE) cancer therapy and Bispecific Killer Engager (BiKE). Both platforms have been licensed by Oxis. The BiKE therapy, OXS-1550, is currently in an FDA Phase 1/Phase 2 clinical trial in Minnesota.
Both treatments empower the body's immune system to identify and selectively kill cancer cells, while leaving healthy cells alone.
Dr. Vallera has spent 35 years with the University of Minnesota's cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company website: www.oxis.com.
Media contact:
Stuart Pfeifer, Sitrick & Co.
(310) 788-2850, or spfeifer@sitrick.com
SOURCE: Oxis International Inc.
© Copyright © 2017 Accesswire. All rights reserved.
Nonsense. Most biotech companies are in a similar situation and trade dollars.
$OXIS managed to get through phase 1 in a similar financial situation, see filings from 2014 and it´s possible they will find a partner and will continue.
You think a pharma stock with active FDA trial in phase 1/2 is only worth a $1.7m market cap? LOL
OXIS is massive undervalued!
The Estimated Primary Completion Date of $OXIS cancer drug in
FDA phase 1/2 is June 2017. Any positive update about this trial would move it up huge!
https://clinicaltrials.gov/ct2/show/study/NCT02370160?term=DT2219ARL&rank=2#contacts
"Estimated Enrollment: 44
Study Start Date: December 2015
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)"
If you research "DT2219ARL"and "pubmed",many peer review articles. Drug has huge potential, that´s a lot space from a $1,7m market cap if the drug has the potential to cure cancer!
And Oxis is in the process of acquiring more high potential drugs.
I would like to get an update about this:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129643556
OXIS Biotech Scientific Advisory Board Member to Address Cancer Immunotherapy Conference in China
http://finance.yahoo.com/news/oxis-biotech-scientific-advisory-board-120000335.html
LOS ANGELES, CA / ACCESSWIRE / March 21, 2017 / Oxis International Inc. (OTCQB: OXIS) (Euronext Paris OXI.PA) announced today that Dr. Daniel Vallera, a member of the Scientific Advisory Board of its wholly owned subsidiary, Oxis Biotech Inc., has been invited to speak at the 15th National Conference of Tumor Immunotherapy on June 22, 2017, in Hefei, China.
Dr. Vallera, Director of the section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he will discuss two immunotherapy cancer treatments that he helped develop -- Trispecific Killer Engager (TriKE) and Bispecific Killer Engager (BiKE). Both platforms have been licensed by Oxis.
The treatments empower the body's immune system to identify and selectively kill cancer cells, while leaving healthy cells alone.
Dr. Vallera was instrumental in the development of Oxis' promising cancer therapy, OXS-1550, which is currently in an FDA Phase 1/Phase 2 clinical trial in Minnesota.
The National Conference of Tumor Immunotherapy focuses on research, technology, clinical practice and government policy related to tumor immunology and immunotherapy. About 500 people are expected to attend.
Anthony Cataldo, Chairman and Chief Executive Officer of Oxis, said Dr. Vallera's invitation is an indication that his work is widely recognized by his peers.
"We have received many requests for more information about the BiKE and TriKE platforms we have licensed from the University Of Minnesota," Mr. Cataldo said. "The biotech community realizes the potential for this technology and how it addresses the future of 'Targeted Immunotherapy.'"
Dr. Vallera has spent 35 years with the University of Minnesota's cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.
About Oxis Biotech, Inc.:
Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
The Estimated Primary Completion Date of $OXIS cancer drug in
FDA phase 1/2 is June 2017. Good catalyst and not far away.
https://clinicaltrials.gov/ct2/show/study/NCT02370160?term=DT2219ARL&rank=2#contacts
"Estimated Enrollment: 44
Study Start Date: December 2015
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)"
People should research the cancer drug "DT2219ARL"and "pubmed",many peer review articles.
OXIS seems to be purchasing the licensing rights to 4 mainline drugs with high potential.
Company should find other ways of raising money...but i cannot complain after i bought shares because of it.
The comment below sounds like EFLO lost their assets.
Where is the 8-k?
Assets are $53m worth. This is a material event! And what did shareholders get? Nothing!
Shares of insiders were purchased at $1+. They could not even sell. And now a known boiler room pump and dump artist took over. Hm...
http://www.yukon-news.com/letters-opinions/day-1-issue-yukons-oil-and-gas-industry-on-life-support/
Richard wrote:
12:12pm Thursday November 17, 2016
"Of course if our columnist had done just a little bit more research… say on EMR’s Oil and Gas webpage, he would know that the Kotaneelee fields are currently owned and operated by Apache Canada after EFLO Energy went bust. Having this facility owned by a larger, more reputable company like Apache rather than a fly by night investment outfit like EFLO will mean good things in the future (even if it only means the site will be properly rehabilitated when they’re done with it)."
EFLO has a new ceo, RICHARD W DONALDSON:
http://nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=Qv8dK%252b8IfJIY5Q%252f%252fgoQ1qg%253d%253d
6,2m float, 34,8m o/s:
Not sure if there is a plan, website is not up.
http://ir.oxis.com/
"OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world's leading cannabinoid researchers and institutions to advance its technologies."
This was filed with the SEC for example:
"In addition to the company’s current focus, a complimentary business opportunity has emerged in the form of cannabinoids and their impact on several types of diseases.
Oxis Biotech, a wholly owned subsidiary, will address this specific sector.
Oxis Biotech is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from our
intended proprietary cannabinoid product platform in a broad range of disease areas.
We intend to develop CBD therapeutics through proven
drug discovery and development processes, creating an intellectual property portfolio and utilizing our regulatory and manufacturing
expertise. Our CBD program is intended to support the submission of a New Drug Application, or NDA, in cancer-related indications with
the U.S. Food and Drug Administration, or FDA, and in other markets around the world. We plan to develop a deep pipeline of cannabinoid
product candidates and seek patents available to us from several sources including the NIH"
CFO worked for GBLX, a cannabis company. I guess they have plans in this sector. Would be good if there is an update about the progress.
Did anyone talk with the company recently?
There is only one potential risk i see, and i would like to get confirmation this risk doesn´t exist.
Need confirmation there is a positive plan for shareholders and the stock.
There is a new corporation on Sunbiz, Invgen LLC and they registered also the domain invgen.com. I wonder if this is maybe connected.
There is also another new corporation on Sunbiz, Abopco LLC, but this one doesn´t sound like a public company.
If this potential risk i see doesn´t exist, it´s very stupid that INNI trades at this level btw.
It traded very different few months ago, in a moment stock had the suspension risk because of delinquent status.
Who are these idiots who sell at .01?
Wow, this looks like it could be the next O W C P.
It has everything: Clinical fda trials, patents, pharma and cannabis sector, QB, great share structure, good news flow, Nasdaq management.
I cannot believe they dilute at this level. I will buy more next week. These stocks you never get at .01.
Not sure if this is the bottom, but it will go up sooner or later and probably very high.
SS has not changed much to when it traded up to $24.
The only question is, is there a plan for the stock. If the answer is yes, there is no limit with $INNI share structure.
You give me a hard time to accumulate with these posts. Can you not go on vacation for 2 months? ;)
Getting close. $AWON
Company restructured only debt last years and wasn´t in business.
I believe Asa was responsible to restructure debt. Loomis was only on board of directors since 2014.
Question is, why did Loomis take over if there is not a plan for the future?
Looking at his resume, i doubt he would do it.
New CEO L. John Loomis:
L. John Loomis managed Arab National Bank($700m PROFIT, $1,5b sales, $40b assets, 5000 employees)
see CISCO Deal on CISCO website, Loomis was mentioned:
CISCO---> https://newsroom.cisco.com/press-release-content?articleId=4864713
https://www.forbes.com/companies/arab-national-bank/
He was COO of Gulf International Bank($300m revenue):
https://www.gib.com/
https://en.wikipedia.org/wiki/Gulf_International_Bank
----> https://people.bayt.com/l-john-loomis-11840198/
John was ceo of ITS ---> $300m+ revenue, 1500+ employees:
http://www.bobsguide.com/guide/news/2013/May/21/its-restructures-to-face-new-macroeconomic-and-business-dynamics/
https://en.wikipedia.org/wiki/International_Turnkey_Systems_Group
Hopefully there is a good plan! John has some interesting connections and he managed also Nasdaq companies.
$INNI NEW CEO:
L. John Loomis managed Arab National Bank($700m PROFIT, $1,5b sales, $40b assets, 5000 employees)
see CISCO Deal on CISCO website, Loomis was mentioned:
https://newsroom.cisco.com/press-release-content?articleId=4864713
https://www.forbes.com/companies/arab-national-bank/
He was COO of Gulf International Bank($300m revenue):
https://www.gib.com/
https://en.wikipedia.org/wiki/Gulf_International_Bank
----> https://people.bayt.com/l-john-loomis-11840198/
John was ceo of ITS ---> $300m+ revenue, 1500+ employees:
http://www.bobsguide.com/guide/news/2013/May/21/its-restructures-to-face-new-macroeconomic-and-business-dynamics/
https://en.wikipedia.org/wiki/International_Turnkey_Systems_Group
$INNI NEW CEO:
L. John Loomis managed Arab National Bank($700m PROFIT, $1,5b sales, $40b assets, 5000 employees)
see CISCO Deal on CISCO website, Loomis was mentioned:
https://newsroom.cisco.com/press-release-content?articleId=4864713
https://www.forbes.com/companies/arab-national-bank/
He was COO of Gulf International Bank($300m revenue):
https://www.gib.com/
https://en.wikipedia.org/wiki/Gulf_International_Bank
----> https://people.bayt.com/l-john-loomis-11840198/
John was ceo of ITS ---> $300m+ revenue, 1500+ employees:
http://www.bobsguide.com/guide/news/2013/May/21/its-restructures-to-face-new-macroeconomic-and-business-dynamics/
https://en.wikipedia.org/wiki/International_Turnkey_Systems_Group
Float only 10m shares.
Share Structure
Market Value1 $1,106,615 a/o Mar 02, 2017
Authorized Shares 750,000,000 a/o Jan 18, 2017
Outstanding Shares 85,784,100 a/o Jan 18, 2017
Float 10,583,860 a/o Jan 18, 2017
Par Value 0.001
On watch for new business without r/s!
People who sell like idiots a 10m float stock at .01, after the first filings since 2 years hit, in a moment stock is down 90%(traded up to .80 when company filed), will be very sorry IMHO.
BMIC is hungry for your shares! :)
He bought all these shares yesterday. Ask yourself why!
AWON pink current now.
http://www.otcmarkets.com/stock/AWON/quote
Looks good
Yes he was ceo of BYOC and now he is again ceo. It sounds like he got the shell back, probably because of SEC issues with the previous management.
Not sure if there is a plan for the shell, could take a long time.
The Shainbergs are involved and Michael Walczak!
They used this time the Hebrew version of Joshua. This was the reason i could not find anything when i resarched Yeshua Shainberg!
BAYP, EMLL, GMND... Sorry to say but you are lost! Dilution scams, reverse splits, not well executed pump and dumps! End is no bid!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113200923
https://www.sec.gov/litigation/aljdec/2006/id317lam.pdf
https://www.sec.gov/alj/aljorders/2006/3-12172.pdf
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65278070
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=113301864
https://www.google.com/search?hl=en&q=Joshua+Shainberg+sec&ei=Xf-XWNjcEIbeU4rOr6gP&gws_rd=cr
Here is one informative post about Adam Tracy:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128434976
"As you can see by this lawsuit filed against Adam Tracy and Christopher Davies by Harvey Romanek (the person that bought the GOFF shell), Christopher Davies is a silent partner in the Adam Tracy shell hijacking/flipping scheme
https://promotionstocksecrets.com/wp-content/uploads/2017/01/GOFFTracyDaviesComplaint.pdf
The GOFF CEO sued Adam Tracy and Christopher Davies (the two people he paid to gain control of the GOFF shell) because they told him it was a clean shell when GOFF is far from clean. It is the subject of a Criminal Complaint.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124181041
Because of the dirty past of GOFF, Harvey Romanek couldn't get FINRA to approve any corporate actions for the ticker leaving him in control of a useless/worthless shell.
Besides the GOFF lawsuit, Adam Tracy has plenty of other problems including an SEC investigation and two more legal proceedings filed against him because of shells he hijacked then sold"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128216683
https://promotionstocksecrets.com/wp-content/uploads/2016/07/AdamSTracyShamIPOs.pdf
https://promotionstocksecrets.com/wp-content/uploads/2016/08/SECAdamTracyExhibitB.pdf
https://promotionstocksecrets.com/wp-content/uploads/2016/07/AdamSTracy.pdf
https://promotionstocksecrets.com/wp-content/uploads/2017/01/TRONEx_Parte_Application_for_Order_Shortening_Time_to_Hear_Motion_to_Set_Aside_Order_Appointing_Custodi_Epap.pdf
https://promotionstocksecrets.com/wp-content/uploads/2017/01/GFOffshorevsTracyCIVSshell.pdf
http://investorshub.advfn.com/boards/replies.aspx?msg=128220404
It´s important to keep it real and i´m sure these information are very appreciated.
Of course i wonder why there was not one word about it in this informative board with real informations and about the $1m with minimum investment of $500 which company wants to raise, but now it´s here!
Doing it all right and merging into a Adam Tracy custodian shell?
http://nvsos.gov/SOSEntitySearch/CorpDetails.aspx?lx8nvq=o3IMw21taJYzpIJXrkfvQQ%253d%253d&nt7=0
How many Adam Tracy custodian shells did well?
Which solid company would merge into a hijacked Adam Tracyshell?
You know SEC investigates him. Sooner or later all will get suspended!
How many times did FINRA approve a corporate action for a Adam Tracy shell? I know only one stock! 100 shells and only one corporate change was approved!
Adam Tracy is also the legal counsel, very trustworthy! He is not gone, fully involved in EBYH.
http://www.otcmarkets.com/research/service-provider/Securities-Compliance-Group-Ltd.?id=4847&b=n&filterOn=3
Company wants to raise $1m, minimum investment only $500, sounds desperate, dilution very likely:
http://www.newestfilings.com/240358-strainsforpains-inc
Does this company have only a gmail email address? Very professional and another right step i guess.
The ceo is absolutely unknown, probably only one of Tracy´s puppets. THere is absolutely nothing to find!
Website has a proxy whois. Yes, this sounds so right!
One of the best mergers of the last 20 years, right? lol
Wrong, no reverse split is coming. It´s cancelled.
This is what the same management has done with ATHI before SEC suspended it for fraud:
Capital Change=shs decreased by 1 for 1000 split Pay date=01/26/2012
Capital Change=shs decreased by 1 for 2400 split Ex-date=04/29/2014.
Capital Change=shs decreased by 1 for 10000 split. Pay date=12/28/2015
Black Shopping Channel had $1-5m revenue in a moment pr was released about $750m revenue, filed with the SEC in 2013.
What else do you need? Why did you buy? Because people posted it has $750m revenue! You have now a SEC filing which shows pr was a lie!
You have proofs that management was in stocks involved which ended with SEC suspension because of fraud.
No reviews to find, only complaints! If this would be a large company there would be 1000 reviews.
They will try to wipe existing shareholders out! This is obvious fraud!
It´s was never offline, active and unchanged since years.
http://web.archive.org/web/*/http://www.videorivernetworks.com/
The website is up since years: http://web.archive.org/web/*/http://www.videorivernetworks.com/